Related Experiment Videos
Development of a second generation group B meningococcal vaccine
C E Frasch1, C T Sacchi, M C Brandiolone
1Center for Biologics Evaluation and Research, Division of Bacterial Products, Bethesda, Maryland.
NIPH Annals
|December 1, 1991
Summary
New outer membrane protein vaccines targeting group B Neisseria meningitidis show promise. Vaccines with iron-regulated proteins in depleted vesicles are immunogenic, potentially improving protection against meningococcal disease.
Area of Science:
- Microbiology
- Vaccinology
- Immunology
Background:
- Outer membrane protein (OMP) vaccines are effective against group B Neisseria meningitidis (MenB).
- Current OMP vaccines require improved protection extent and duration.
- Iron-regulated proteins are crucial for bacterial survival and potential vaccine targets.
Purpose of the Study:
- To develop a second-generation MenB vaccine.
- To evaluate vaccines containing iron-regulated proteins in lipopolysaccharide-depleted outer membrane vesicles.
- To test the hypothesis that antibodies to iron-regulated proteins are bactericidal or block iron uptake.
Main Methods:
- Development of vaccines using iron-regulated proteins.
- Lipopolysaccharide (LPS) depletion from outer membrane vesicles (OMVs).
- Immunization of mice with developed vaccines.
Main Results:
- Preliminary studies indicate immunogenicity in mice.
- Vaccines containing iron-regulated proteins were successfully developed.
- LPS-depleted OMVs were used as vaccine carriers.
Conclusions:
- Vaccines containing iron-regulated proteins are immunogenic in mice.
- This approach is a promising strategy for a second-generation MenB vaccine.
- Further studies are warranted to assess bactericidal activity and protection duration.